Cost-effectiveness of disease-modifying therapy for multiple sclerosis- A population-based study
Neurology®, 07/29/2011Noyes K et al.
Compared to treating patients with all levels of disease, starting disease–modifying therapies(DMT) earlier was associated with a lower (more favorable) incremental cost–effectiveness ratio compared to initiating treatment at any disease state. Use of DMT in multiple sclerosis(MS) results in health gains that come at a very high cost.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.